AgomAb Therapeutics NV (ADR) (AGMB) Live Share Price, Invest From India

AgomAb Therapeutics NV (ADR) Stock Performance

as on June 27, 2026 at 2:15 pm IST

Day's Low
Day's High
$12.62
Day's Price Range
$13.53
$13.81
8.62%
Downside
-2.03%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$13.81
100.00%
Downside
-100.00%
Upside

AgomAb Therapeutics NV (ADR) share price movements today

Previous Close: $13.43
Open: $13.19
Volume: 293.0K
Day's Low - High: $12.62 - $13.53

AgomAb Therapeutics NV (ADR) Historical Returns

1 Month Return: + 21.54 %
3 Month Return: + 13.14 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

AgomAb Therapeutics NV (ADR) Stock Fundamentals & Key Indicators

Check AgomAb Therapeutics NV (ADR) market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$655.5M

EPS (TTM)

-1.8143

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-39.22%

AgomAb Therapeutics NV (ADR) vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of AgomAb Therapeutics NV (ADR) with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
AgomAb Therapeutics NV (ADR)	NA	$655.5M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$39.3B	67.15%	74.07	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$120.6B	147.08%	28.17	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$65.4B	12.64%	15.22	29.65%	0.58%

Indian Investors' Interest in AgomAb Therapeutics NV (ADR) Stock

Search interest for AgomAb Therapeutics NV (ADR) Stock has increased by 500% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 29, 2026 to June 28, 2026

Change:500% versus previous 30 day period

AgomAb Therapeutics NV (ADR) Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2024	Dec 2025
Total Revenue	-	-
Gross Profit	-	-
Operating Income	-11	-16
EBITDA	-11	-17
Interest Expense	0	0
Depreciation	0	0
Income Before Tax	-11	-17
Income Tax Expense	0	-
Net Income	-12	-17
Net Profit Margin	0.00%	0.00%

AgomAb Therapeutics NV (ADR) Annual Profit & Loss

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-
Gross Profit	-	-	-	0
Operating Income	-22	-31	-48	-59
EBITDA	-10	-11	-45	-62
Interest Expense	0	0	0	0
Depreciation	0	0	0	0
Income Before Tax	-10	-12	-46	-62
Income Tax Expense	-2	0	0	0
Net Income	-8	-12	-48	-60
Net Profit Margin	0.00%	0.00%	0.00%	0.00%

AgomAb Therapeutics NV (ADR) Quarterly Cash Flow

All numbers in Millions USD

	Dec 2025	Mar 2026
Net Income	-17	-11
Operating Cash Flow	-13	-12
Investing Cash Flow	-30	0
Financing Cash Flow	0	81
Change in Cash	-43	68

AgomAb Therapeutics NV (ADR) Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Net Income	-11	-46	-62
Operating Cash Flow	-24	-46	-51
Investing Cash Flow	-	-	-33
Financing Cash Flow	79	96	0
Change in Cash	94	49	-85

Global Institutional Holdings in AgomAb Therapeutics NV (ADR)

Funds	Holdings
LMR Partners LLP	0.61%
Cormorant Asset Management, LLC	5.01%
Andera Partners	3.12%
TCG Crossover Management, LLC	4.17%
FMR Inc	2.96%

See all

Insights on AgomAb Therapeutics NV (ADR)

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, AGMB stock has moved up by 25.8%

About AgomAb Therapeutics NV (ADR)

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Organisation	AgomAb Therapeutics NV (ADR)
Headquarters	Posthoflei 1/6, Antwerp, Belgium, 2600
Industry	Biotechnology
CEO	Dr. Tim Knotnerus MSc, Ph.D.
E-voting on shares	Click here to vote

Key Management of AgomAb Therapeutics NV (ADR)

Name	Title
Dr. Philippe Wiesel M.D.	Chief Medical Officer
Dr. Paul Van Der Horst Ph.D.	Chief Business Officer
Dr. Andrea Sáez Borderías Ph.D.	Chief Development Officer
Dr. Tim Knotnerus MSc, Ph.D.	CEO & Executive Director
Mr. Paolo Michieli Ph.D.	Founder, Senior Advisor & Member of Scientific Advisory Board
Mr. Pierre Kemula B.Sc.	Chief Financial Officer
Sofie Van Gijsel	Vice President of Investor Relations
Ms. Ellen Lefever	General Counsel

FAQs

What is AgomAb Therapeutics NV (ADR) share price today?

AgomAb Therapeutics NV (ADR) share price today is $13.81 as on June 27, 2026 at 8:45 am IST at the close of the market. AgomAb Therapeutics NV (ADR) share today touched a day high of $13.53 and a low of $12.62.

What is the 52 week high and 52 week low for AgomAb Therapeutics NV (ADR) share?

AgomAb Therapeutics NV (ADR) share touched a 52 week high of $0 on January 1, 1970 and a 52 week low of $0 on January 1, 1970. AgomAb Therapeutics NV (ADR) stock price today i.e. June 27, 2026 at 8:45 am IST is closed at $13.81,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is AgomAb Therapeutics NV (ADR)'s market capitalisation today?

AgomAb Therapeutics NV (ADR) market capitalisation is $0.00T as on June 27, 2026 at 8:45 am IST.

How to invest in AgomAb Therapeutics NV (ADR) Stock (AGMB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for AgomAb Therapeutics NV (ADR) on INDmoney app. Click on Buy button. You can invest as low as $1.5 in AgomAb Therapeutics NV (ADR) Shares that will get you 0.1086 shares as per AgomAb Therapeutics NV (ADR) share price of $13.81 per share as on June 27, 2026 at 8:45 am IST.

What is the minimum amount required to buy AgomAb Therapeutics NV (ADR) Stock (AGMB) from India?

Indian investors can start investing in AgomAb Therapeutics NV (ADR) (AGMB) shares with as little as ₹94.3 or $1 (as of June 28, 2026 at 1:37 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹943.00 in AgomAb Therapeutics NV (ADR) stock (as per the Rupee-Dollar exchange rate as on June 28, 2026 at 1:37 am IST). Based on AgomAb Therapeutics NV (ADR) share’s latest price of $13.81 as on June 27, 2026 at 8:45 am IST, you will get 0.7241 shares of AgomAb Therapeutics NV (ADR). Learn more about fractional shares .